Peptide Education
Tesamorelin
A growth hormone-releasing factor analog with a narrow approved indication.
Clinical services are not available yet. GetPeptides has not launched medical visits, prescriptions or pharmacy delivery in any state. Nothing you do here enrolls you in treatment.
Regulatory status
At least one branded product containing this substance is FDA-approved for a defined use in a defined population. Compounded versions of the same active ingredient are not themselves FDA-approved, are not reviewed by the FDA before marketing, and are not confirmed by the FDA to have the same safety or effectiveness as the approved brand.
This page is editorial content written by the GetPeptides team from the publicly available regulatory sources cited below. It has not been reviewed or approved by a qualified independent clinician or pharmacist, and it is not medical advice.
Educational information only — not medical advice. GetPeptides does not sell, prescribe or dispense this substance. A consultation never guarantees a prescription.
FDA-approved products
Egrifta (reduction of excess abdominal fat in adults with HIV-associated lipodystrophy).
Regulatory notes
Use outside the approved indication is off-label and the evidence base is more limited.
Risks and limitations
Labeling describes injection-site reactions, fluid retention, joint pain and effects on blood sugar.
Sources
- DailyMed: Tesamorelin (Egrifta) labeling — editorial source list 2026-10-14
Ask about this page
The assistant is temporarily unavailable. For questions about Tesamorelin, please see the published information on this page, or contact a licensed clinician via the "Find a Licensed Clinician" directory.